Citation APA
de Azambuja, E., Abdel Azim, H. H., Holmes, A. A., Holmes, E., Piccart-Gebhart, M., Di Cosimo, S., Swaby, R. R., Untch, M., Jackisch, C., Lang, I., Smith, I., Boyle, F., Xu, B., Barrios, C. H., Perez, E. A., Kim, S.-B., Kuemmel, S., Huang, C. S., Vuylsteke, P., Hsieh, R. K., Gorbunova, V., Eniu, A., Dreosti, L., Tavartkiladze, N., Gelber, R., Eidtmann, H., & Baselga, J. (2014). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet oncology, 15(10), 1137-1146. doi:10.1016/S1470-2045(14)70320-1
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/186935